Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations

Haznedaroglu I. C.

EXPERT OPINION ON PHARMACOTHERAPY, vol.14, no.15, pp.2005-2010, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 14 Issue: 15
  • Publication Date: 2013
  • Doi Number: 10.1517/14656566.2013.833185
  • Journal Name: EXPERT OPINION ON PHARMACOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2005-2010
  • Hacettepe University Affiliated: No

Abstract

Introduction: The aim of this paper is to indicate optimal tyrosine kinase inhibitor (TKI) administration practices based on European LeukemiaNet (ELN) 2013 recommendations for chronic myeloid leukemia (CML). Likewise, current concerns of undertreatment and overtreatment with TKIs during the long-term clinical course of CML will be outlined.